ARS Pharmaceuticals Inc reports results for the quarter ended June 30 - Earnings Summary

• ARS Pharmaceuticals Inc SPRY.OQ reported a quarterly adjusted loss of 46 cents​​ per share for the quarter ended June 30, lower than the same quarter last year, when the company reported EPS of -13 cents. The mean expectation of six analysts for the quarter was for a loss of 47 cents per share. Wall Street expected results to range from -66 cents to -37 cents per share.

• Revenue rose 3,043.4% to $15.72 million from a year ago; analysts expected $13.78 million.

• ARS Pharmaceuticals Inc's reported EPS for the quarter was a loss of 46 cents​.

• The company reported a quarterly loss of $44.88 million.

• ARS Pharmaceuticals Inc shares had fallen by 4.5% this quarter and gained 57.9% so far this year.

FORECAST CHANGES

• The mean earnings estimate of analysts had risen by about 0.4% in the last three months.​

• In the last 30 days, there have been no earnings estimate revisions by analysts covering the company.

RECOMMENDATIONS

• The current average analyst rating on the shares is "strong buy" and the breakdown of recommendations is 6 "strong buy" or "buy," no "hold" and no "sell" or "strong sell." The average consensus recommendation for the biotechnology & medical research peer group is "buy."

• Wall Street's median 12-month price target for ARS Pharmaceuticals Inc is $30.00, about 44.5% above its last closing price of $16.66

This summary was machine generated from LSEG data August 13 at 01:30 p.m. UTC. ​All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)